Dr. Voss on the Case for Neoadjuvant Treatment in Kidney Cancer

Video

In Partnership With:

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

Voss says that there is debate around whether there is merit to using neoadjuvant therapy in patients with kidney cancer who have non-metastatic disease versus adjuvant therapy. One of the concerns with neoadjuvant approaches is that preoperative therapy with a systemic agent may delay surgery. Another concern is that there may be toxicities from neoadjuvant therapy that may get in the way of surgery.

Voss says that recent data suggest that these concerns are probably not well founded. Drugs that would be used as neoadjuvant treatment would not necessarily delay time of surgery, he adds, and even if they did—delaying surgery a few months is not likely to affect outcomes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD